文献速递贫血与红细胞疾病

每日两次去铁酮在地中海贫血、镰状细胞病或其他贫血患者中的真实世界安全性

Real-world safety profile of twice a day deferiprone in patients with thalassemia, sickle cell disease, or other anemias.
PubMed 文献 · Blood Adv · 2026-01-01

本研究基于美国Ferriprox Total Care登记处数据,评估每日两次去铁酮(DFP)在2020年7月至2023年8月期间转诊的425例患者中的安全性,其中348例接受至少一次DFP发货并纳入安全性分析组。主要诊断为地中海贫血综合征129例、镰状细胞病189例、其他贫血30例,平均暴露343.0天。结果显示每日两次DFP耐受良好,安全性特征与每日三次制剂一致,未观察到新的安全性问题。

要点

  • 每日两次去铁酮真实世界安全性特征与每日三次制剂一致
  • 中性粒细胞减少和粒细胞缺乏症罕见,分别报告1.7%和0.6%,所有病例均恢复
  • 26例死亡结局均未评估为与去铁酮治疗相关

核心结论

  • 每日两次去铁酮在真实世界临床实践中耐受良好,安全性特征与每日三次制剂一致,未观察到新的安全性问题。

研究设计与样本

  • 基于美国Ferriprox Total Care登记处的真实世界研究,纳入2020年7月1日至2023年8月31日期间转诊使用每日两次去铁酮的患者。

主要发现

  • 425例转诊患者中348例接受至少一次DFP发货并纳入安全性分析组,主要诊断为地中海贫血综合征129例、镰状细胞病189例、其他贫血30例。
  • 平均(标准差)DFP暴露时间为343.0(281.9)天。
  • 共报告1021例不良事件和369例严重不良事件,最常见不良事件主要为胃肠道相关或与基础疾病相关。
  • 中性粒细胞减少和粒细胞缺乏症分别报告于1.7%和0.6%的患者,所有病例均恢复。
  • 26例死亡结局均未评估为与DFP治疗相关。

临床怎么用

  • 每日两次去铁酮可作为改善治疗依从性的选择,其真实世界安全性特征与每日三次制剂一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Iron overload is a significant cause of transfusion-related morbidity and mortality. Deferiprone (DFP) is an established oral iron chelator approved for the treatment of transfusional iron overload in patients with thalassemia, sickle cell disease (SCD), or other anemias. Although DFP was initially approved as a thrice daily formulation, a twice daily formulation was developed to improve patients' treatment adherence. Here, we assess the safety of DFP twice daily in patients with thalassemia, SCD, or other anemias in real-world clinical practice in the United States. Data for patients referred for DFP twice daily between 1 July 2020 and 31 August 2023 were obtained from the Ferriprox Total Care Registry. The frequencies of adverse events (AEs), serious AEs (SAEs), AEs of special interest, and fatal outcomes were assessed. Of the 425 patients referred to the registry, 348 received ≥1 DFP shipment, and was designated the safety analysis group. The primary diagnosis was a thalassemia syndrome in 129, SCD in 189, and other anemia in 30 patients. Mean (standard deviation) DFP exposure was 343.0 (281.9) days. In total, 1021 AEs and 369 SAEs were reported. As seen with the thrice daily formulation, the most common AEs associated with DFP twice daily were predominantly gastrointestinal or related to underlying disease. Cases of neutropenia and agranulocytosis were rare, reported in 1.7% and 0.6% of patients, respectively, and all cases recovered. None of the 26 fatal outcomes reported were assessed as related to DFP treatment. DFP twice daily was well tolerated in real-world clinical practice, and its safety profile was consistent with DFP thrice daily. No new safety concerns were observed.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Sheth S, Lal A, Appiah-Kubi A, et al. Real-world safety profile of twice a day deferiprone in patients with thalassemia, sickle cell disease, or other anemias. Blood Adv. 2026. PMID: 42241705. doi:10.1182/bloodadvances.2025019368

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。